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Abstract
Introduction Studies measuring the effectiveness of risk
minimization measures (RMMs) submitted by pharma-
ceutical companies to the European Medicines Agency are
part of the post-authorization regulatory requirements and
represent an important source of data covering a range of
medicinal products and safety-related issues. Their objec-
tives, design, and the associated regulatory outcomes were
reviewed, and conclusions were drawn that may support
future progress in risk minimization evaluation.
Methods Information was obtained from risk management
plans, study protocols, clinical study reports, and assess-
ment reports of 157 medicinal products authorized for
cardiovascular, endocrinology, and metabolic indications.
We selected observational studies measuring, as outcomes
of interest, the relationship between the RMMs in place
and (1) implementation measures, such as clinical knowl-
edge or physicians‘ compliance to recommendations con-
tained in the RMMs; and (2) occurrence or reduced
severity of the adverse drug reactions for which the RMMs
were required.
Results Of 59 eligible studies (24 completed, 35 ongoing),
44 assessed implementation measures, whereas only 15
assessed safety outcomes (1 study as a single endpoint and
14 studies with other endpoints). Fifty-one studies used
non-experimental designs and 25 studies employed elec-
tronic healthcare databases for analysis. Of the 24 com-
pleted studies, 17 were considered satisfactory and
supported immediate regulatory decision making, 6 were
considered inconclusive and required new evaluations, and
1 was terminated early because new safety restrictions
were required, thereby necessitating a new evaluation.
Compliance with agreed deadlines was considered
acceptable in 21 of 24 completed studies; the average time
for a submission was 37 months (standard deviation± 17),
with differences observed by type of data source employed.
Conclusions Three important gaps in the evaluation plans
of RMMs were identified: lack of early feedback on
implementation, limited evaluation of safety outcomes, and
inability to provide information on the effectiveness from
an integrated measurement of different elements of a set of
risk minimization tools. More robust evidence is needed to
advance regulatory science and support more rapid
adjustment of risk minimization strategies as needed.
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Key Points
To measure the impact of pharmacovigilance
activities, we reviewed industry-sponsored studies
evaluating the effectiveness of risk minimization
measures (RMMs) received by the European
Medicines Agency.
Few studies were designed to measure the impact of
RMMs in reducing the occurrence of adverse drug
reactions, or used an appropriate study design to
evaluate their effectiveness.
Optimal evaluation may be hampered by the limited
data available when the RMM is introduced, and by
the time required to obtain this information.
Efficient evaluation may benefit from an integrated
measurement of the different elements of the RMMs.
This should help regulators to gain timely
information and undertake prompt adjustment of risk
minimization strategies as needed.
1 Introduction
The European Union (EU) Risk Management Plan (EU-
RMP) was introduced in 2005 as the instrument for plan-
ning pharmacovigilance activities and risk minimization
measures (RMMs) for new chemical entities and biologi-
cals, as well as for generics when additional risk man-
agement activities were identified for the reference product
[1]. In July 2012, with the implementation of the current
EU pharmacovigilance legislation, an EU-RMP became
mandatory for all newly authorized products [2, 3]. The
EU-RMP aims to ensure that the benefit-risk profile of a
medicinal product is managed optimally during the product
lifecycle, knowledge gaps at the time of authorization are
elucidated, and risks are further quantified and character-
ized over time [4].
The three pillars of the EU-RMP are: (1) the safety
specification that describes the safety concerns (any
important risks and missing information that could affect
the benefit-risk profile of the medicinal product or have
implications for public health); (2) the pharmacovigilance
plan to characterize these safety concerns (routine and
additional activities); and (3) the risk minimization plan to
mitigate the risks in clinical practice [5].
For all medicinal products, the EU-RMP includes rou-
tine RMMs, meaning the provision of information and
recommendations in the summary of product
characteristics (SmPC) and package leaflet (PL), the pro-
duct labeling, a pack size appropriate to the anticipated
treatment duration, and a risk-appropriate legal status of
the product (e.g. prescription-only medicine) [5]. However,
for some drugs routine risk minimization might not be
sufficient and it may be necessary to implement additional
measures, such as the provision of education materials for
healthcare professionals (HCPs) and patients. These addi-
tional RMMs (aRMMs) aim to support a positive benefit-
risk profile, for example, by targeted patient selection or
exclusion, appropriate treatment management (e.g. specific
dosing regimen, relevant testing, and patient follow-up),
and/or early recognition of adverse drug reactions (ADRs)
[6].
The assessment of the effectiveness of RMMs is of
importance to ensure that their objectives are fulfilled or to
provide evidence that further amendments are warranted.
This knowledge can also be used to inform on optimal risk
minimization strategies for other medicines to maintain a
positive benefit-risk profile [5, 7, 8]. This activity has in
fact been recognized as one of the key elements of a broad
strategy established in January 2016 by the EMA Phar-
macovigilance Risk Assessment Committee (PRAC) to
measure the impact of pharmacovigilance activities that
may enable the monitoring of important pharmacovigilance
outputs and regulatory actions and contribute to the further
development of the proactive EU pharmacovigilance sys-
tem [9].
Available evidence shows that studies measuring the
effectiveness of RMMs to date are mainly focused on
medicinal products that were subject to extensive risk
communication because of a serious safety-related issue
[10], employed secondary data for collecting information
on drug exposure and related health outcomes [11, 12], or
used suboptimal research designs and analytic methods,
making the results susceptible to bias [13, 14].
Studies submitted by pharmaceutical companies to the
competent authorities represent an additional source of data
covering a range of products and safety-related issues. The
EU pharmacovigilance legislation [2] defines these as post-
authorization safety studies (PASS) and envisages detailed
guiding principles for their conduct, such as their inclusion
in the EU-RMP of each medicinal product, the format of
protocols, abstracts and clinical study reports (CSRs), and
the mandatory submission of the CSR to the competent
authorities for assessment by the agreed deadlines [5, 6].
The present study was conducted to provide an overview
of industry-sponsored studies measuring the effectiveness
of RMMs included in the EU-RMP of medicinal products
in designated therapeutic areas (i.e. cardiovascular,
endocrinology, metabolic), including their objectives,
design, and the associated regulatory outcomes. It also
aimed to assess how these studies were able to support
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decisions by EU regulatory authorities. This should in turn
help to identify enablers and barriers associated with
efforts to evaluate RMMs, to draw conclusions relevant to
the future development in the area of risk minimization
evaluation, including process and methodological
improvement.
2 Methods
2.1 Identification of Centrally Authorized Products
All medicinal products authorized in the EU with a cen-
tralized procedure (i.e. centrally authorized products
[CAPs]) [1] between 1 January 1995 and 31 July 2015 for
cardiovascular, endocrinology and metabolic indications,
and not withdrawn or suspended post-authorization, were
identified. New and known active substances, well-estab-
lished use products, and fixed combination products for
which a full dossier was submitted and assessed by the
European Medicines Agency’s (EMA’s) committees dur-
ing the study period were considered eligible for this
review. All products based on generic, biosimilar, or hybrid
applications (i.e. applications that do not contain a full
dossier but rely on a reference medicinal product) were
excluded. From the eligible products, those with an EU-
RMP either at the time of the marketing authorization or at
any time post-authorization qualified for inclusion in the
current study.
2.2 Data Sources
The EMA public website was used to collect information
on medicinal products, including status after initial autho-
rization (active or withdrawn), legal status (over the
counter [OTC], subject to medical prescription), and
authorization details (e.g. exceptional circumstances,
orphan designation). Information on the type of risk min-
imization (routine vs. additional) and studies measuring the
effectiveness of RMMs was retrieved from the most recent
EU-RMP authorized by the EMA committees (i.e. PRAC
or the Committee for Medicinal Products for Human Use
[CHMP]) and stored in the EMA electronic records man-
agement system. The EMA electronic records management
system was also checked to retrieve further relevant doc-
umentation on the studies measuring the effectiveness of
RMMs, such as information on study protocols, CSRs, and
EMA committees’ assessment reports to collect informa-
tion on the regulatory outcome resulting from the assess-
ment of the CSRs [15].
The EMA core regulatory processes database i.e. the
Model System for Computer-Assisted Drug Registration
(SIAMED) developed by the World Health Organization
was used to retrieve information on medicinal products
authorized on the basis of a hybrid application, as well as
the type of application made by the pharmaceutical com-
panies (i.e. regulatory procedure) resulting in these post-
authorization measures. Information on the publication
status of completed studies was retrieved using the EU
electronic register of post-authorization studies (EU PAS
Register) maintained by the European Network of Centers
for Pharmacoepidemiology and Pharmacovigilance
(ENCePP) [16] and the US registry of studies maintained
by the National Institutes of Health [17]. A PubMed search
was also conducted to check how many studies were
published in the peer-reviewed scientific literature.
2.3 Data Extraction and Classification
Data were extracted by one researcher (DdS) using a pre-
specified standardized data extraction format. Study
selection and classification was then conducted indepen-
dently by two researchers (GM and DdS) and cross-
checked for consistency. Discrepancies in study selection
and classification were resolved by discussion.
All selected studies were classified according to the study
endpoints, the research design, and the type of data source
being used. The following study endpoints adapted from
Prieto et al. [18] were considered: (a) clinical knowledge,
aimed at determining whether the end users have correctly
understood the purpose of the risk minimization tools and
their key messages; (b) clinical behavior, aimed at mea-
suring to what extent the behavior of the targeted stake-
holders (e.g. HCPs, patients, or both) differs from the
recommendations contained in the RMM; (c) safety out-
comes, aimed at correlating the implementation of the
RMM with reduced incidence or reduced severity of ADRs;
(d) multiple outcomes when more than one of the above
endpoints were proposed in the same study.
Research designs were classified into quasi-experimen-
tal and non-experimental. Quasi-experimental designs were
further classified into before-and-after studies and inter-
rupted time series (ITS). In both types of design, the
evaluation of the effect of an intervention is performed by
measuring the study endpoints before and after the intro-
duction of the intervention in the same study population
and by using baseline (pre-intervention) characteristics as a
comparison group [13, 19]. Non-experimental designs only
measure the study endpoints post-intervention. In the
absence of a comparison group, the effect of the inter-
vention can be estimated by using a predefined reference
value, such as the expected outcome frequency in the
general population or in the prelicensing clinical trials.
Non-experimental designs were further classified as retro-
spective or prospective studies according to the time per-
spective for data collection.
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2.4 Study Selection
Study selection was performed using a two-step
approach. First, titles and objectives were reviewed for
all interventional trials and other forms of study included
in the pharmacovigilance plan of the relevant EU-RMPs,
and only observational studies were selected. Second, for
each of the selected studies, protocols and CSRs (where
available) were examined to select the final list. At least
one of the following eligibility criteria were considered
for inclusion: (a) the assessment of the effectiveness of
the RMM (e.g. major changes in the SmPC/PL or
adoption of new educational material for HCPs/patients)
was mentioned as the primary or secondary study
objective; (b) the date of implementation of RMMs was
used as the change point to analyze trends in drug
exposure or incidence of adverse events; (c) the study
was designed to assess the clinical knowledge or
behavior regarding the recommendations contained in
the RMM by using predefined measurable indicators
[20].
2.5 Statistical Analysis
Descriptive statistics for the selected studies were analyzed
as means (standard deviation [SD]), proportions, or count
data, as appropriate. The studies were counted once
regardless of whether they were related to more than one
medicinal product. Conversely, more than one study could
have been related to a single medicinal product or regu-
latory procedure, thus leading to different numbers for
medicinal products and regulatory procedures associated
with the selected studies.
3 Results
Of 297 medicinal products authorized in the observation
period, 55 were withdrawn for commercial or safety rea-
sons, 52 were excluded because they were generic, hybrid
or biosimilar applications, and 33 were excluded because
no RMP was present in the dossiers submitted by the
pharmaceutical companies, neither at the time of the mar-
keting authorization application nor in the post-authoriza-
tion phase (Fig. 1). From the EU-RMP of the remaining
157 medicinal products, 436 studies were identified, of
which 204 were not observational and 173 did not fulfill
our selection criteria. A total of 59 studies (30 for routine
risk minimization, 29 for additional risk minimization)
qualified for the analysis (Fig. 1). The medicinal product
characteristics associated with the selected studies are
described in Table 1.
3.1 Characteristics of the Selected Studies
Table 2 describes the main characteristics of the selected
studies. Approximately half (n = 30) evaluated clinical
behavior, 13 assessed clinical knowledge, and 1 evaluated
multiple endpoints (without safety outcomes). Addition-
ally, safety outcomes were assessed in 15 studies—in 1
study as a single endpoint and in 14 studies measured
simultaneously with other endpoints (i.e. clinical behavior).
A non-experimental design was used in 51 studies;
among them, we observed 43 retrospective studies and 8
prospective studies. Quasi-experimental designs were
applied in 8 studies (1 an ITS and 7 a before/after design);
7 of these studies measured the impact of aRMMs.
Of 59 studies, 25 used electronic healthcare databases
(EHDs) as a source of information (19 for clinical behav-
ior, 6 for multiple endpoints, including safety outcomes),
and 18 used questionnaires (11 for clinical knowledge, 6
for clinical behavior, 1 for multiple endpoints, including
safety outcomes). Of 13 studies using primary data and
retrospective chart review, 8 evaluated safety outcomes.
Stratification by RMM type indicated that EHDs were
mostly used to assess the impact of routine RMMs (16 of
30), whereas questionnaires were mostly used to assess the
effectiveness of aRMMs (11 of 29).
3.2 Regulatory Outcomes
The 59 studies that qualified for this review (both ongoing
and completed) were part of 48 regulatory procedures for
either initial marketing authorization (n = 23) or post-
marketing requirements (n = 25). Among postmarketing
requirements, 10 related to extensions of indication, 6
related to line extensions (i.e. strength, pharmaceutical
form or route of administration), 6 were in EU reviews of
the product’s benefit-risk assessment (i.e. EU referrals), 3
related to emerging safety concerns from two Periodic
Safety Update Report (PSUR) assessments, and one was a
re-analysis of a clinical trial (Table 3; see electronic sup-
plementary material 1).
Table 3 describes the regulatory outcomes of 24 com-
pleted studies submitted to the EMA’s committees for
assessment. Twenty-one CSRs were submitted by the
pharmaceutical companies within the planned deadline.
Nevertheless, in 8 cases the deadline initially planned was
postponed upon request of the pharmaceutical companies
and agreement from the EMA’s committees, mainly
because of low recruitment or low drug uptake.
The average time from the date each study was formally
requested until submission of the CSR to the EMA’s
committees was 37 months (SD± 17) with differences
observed by type of data source employed (questionnaires:
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30 months [SD± 17]; EHDs: 37 months [SD± 14]; retro-
spective chart review: 50 months [SD± 3]; and primary
data collection: 58 months [SD± 12]).
The data presented in the CSRs were considered satis-
factory and supported immediate regulatory decisions in 17
(70.8%) of the 24 completed studies. Further follow-up was
not considered necessary in 13 studies, whereas evidence
of non-compliance with safety restrictions was observed in
4 studies and prompted changes of the product information
(orlistat), new risk communication (insulin glulisine), and a
request for further studies to evaluate safety and efficacy
using a different posology (tolvaptan). The results of six
studies were considered inconclusive because of feasibility
(i.e. low recruitment and low drug uptake) or method-
ological limitations (i.e. lack of external validity of the
selected population and information bias). In two cases
(agalsidase beta, imiglucerase) the EMA committees
accepted the company proposal to monitor the effective-
ness of the RMMs via spontaneous reporting of suspected
ADRs, whereas in the other four cases, new studies were
requested. One physician survey was terminated earlier and
replaced with a drug utilization study (dronedarone)
Eligible medicinal
products (N=157)
Selected 
studies (N=59)
Roune risk 
minimizaon
(N=30)
Screened
studies (N=436)
Addional risk 
minimizaon
(N=29)
Excluded: 
Clinical studies (N=185)
Non-clinical (N=19)
Excluded: 
Observaonal: safety (N=167)
Drug ulizaon only (N=6)
Approved medicinal
products (N=297)
Withdrawn: 
Safety reasons (N=9)
Commercial reasons (N=46)
Excluded: 
Generic/biosimilar/hybrid (N=52)
No Risk Management Plan (N=33)
Fig. 1 Inclusion of eligible products and corresponding selected studies
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Table 1 Medicinal product characteristics associated with the selected studies, stratified by type (routine vs. additional) of risk minimization
measure
Routine [N = 30] (%) Additional [N = 29] (%) Total [N = 59] (%)
Legal status
OTC 4 (13.3) 0 4 (6.8)
Medical prescription 22 (73.4) 20 (69) 42 (71.2)
Restricted medical prescription 4 (13.3) 9 (31) 13 (22)
Authorization details
Exceptional circumstances
Yes 0 3 (10.3) 3 (5.1)
No 30 (100) 26 (89.7) 56 (94.9)
Orphan status
Yes 1 (3.3) 6 (20.7) 7 (11.9)
No 29 (96.7) 23 (79.3) 52 (88.1)
Therapeutic group (ATC)a
Drugs used in diabetes 10 (33.3) 6 (20.7) 16 (27.1)
Antithrombotic agents 6 (20) 7 (24.1) 13 (22)
Other alimentary tract and metabolism products 7 (24.1) 7 (11.9)
Cardiac therapy 5 (17.2) 5 (8.5)
Drugs for treatment of bone diseases 4 (13.3) 1 (3.4) 5 (8.5)
Anti-obesity preparations, excluding diet products 4 (13.3) 1 (3.4) 5 (8.5)
Lipid-modifying agents 1 (3.3) 2 (6.9) 3 (5.1)
Othersa 5 (16.7) 0 5 (8.5)
OTC over the counter, ATC Anatomical Therapeutic Classification (second level)
aIncludes five therapeutic groups for which only one study was requested
Table 2 Characteristics of the selected studies, stratified by type (routine vs. additional) of risk minimization measure
Routine [N = 30] (%) Additional [N = 29] (%) Total [N = 59] (%)
Study endpoints
Clinical knowledge 4 (13.3) 9 (31) 13 (22)
Clinical behavior 22 (73.4) 8 (27.6) 30 (50.8)
Safety outcomes 0 1 (3.4) 1 (1.7)
Multiple (without safety outcomes) 0 1 (3.4) 1 (1.7)
Multiple (with safety outcomes) 4 (13.3) 10 (34.5) 14 (23.7)
Research design
Non-experimental (retrospective) 26 (86.7) 17 (58.6) 43 (72.9)
Non-experimental (prospective) 3 (10) 5 (17.2) 8 (13.6)
Quasi-experimental (before/after) 1 (3.3) 6 (20.7) 7 (11.9)
Quasi-experimental (ITS) 1 (3.4) 1 (1.7)
Data sources
Questionnaires 7 (23.3) 11 (37.9) 18 (30.5)
Electronic healthcare databases 16 (53.3) 9 (31) 25 (42.4)
Retrospective chart reviews 3 (10) 2 (6.9) 5 (8.5)
Primary data collection, including registries 3 (10) 5 (17.2) 8 (13.6)
Othersa 1 (3.4) 2 (6.9) 3 (5.0)
ITS interrupted time-series
aFocused usability testing (2), immunology testing (1)
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Table 3 Main regulatory information of completed studies by active substance and regulatory procedure, stratified by type of RMM
INN [no. of
medicinal
products]
Type of
regulatory
procedure
[year]a
No. of
studies
CSR
submission
(months)b
Study
endpoint
Data source Regulatory outcome Study publication
Routine
Bivalirudin
[1]
EXT
[2007]
1 43 Multiple
(with
safety
outcomes)
Primary data Study considered unsatisfactory
(methodological issues).
Further expansion of the
educational material; new
study requested (see ongoing
studies in electronic
supplementary material 1)
PMID: 24680250
Denosumab
[1]
MA
[2010]
1 47 Clinical
behavior
EHDs Results considered satisfactory;
no further follow-up required
NA
Fondaparinux
[1]
EXT
[2007]
1 49 Clinical
behavior
Chart review Results considered satisfactory;
no further follow-up required
EUPAS6655 (no
results posted)
Fondaparinux
[1]
EXT
[2010]
1 53 Clinical
behavior
Chart review Results considered satisfactory;
no further follow-up required
NCT01406301
(no results
posted)
Insulin
glulisine [1]
EXT
[2008]
3 50 [a] Clinical
knowledge
[b, c]
Clinical
behavior
[a] Questionnaire
[b, c] EHDs
The first study reported
evidence of non-compliance
with safety restrictions; further
requirement for risk
minimization and new studies.
Latest studies considered
satisfactory; no further follow-
up required
NA
Orlistat [1] LE [2008] 2 24 [a, b]
Clinical
behavior
[a, b]
Questionnaire
Studies reported evidence of
non-compliance with safety
restrictions. Further risk
minimization measures and
studies requested (see ongoing
studies in electronic
supplementary material 1)
NA
Pioglitazone
(mono and
FDC) [5]
EXT
[2006]
1 36 Clinical
behavior
EHDs Results considered satisfactory;
no further follow-up required
NA
Rivaroxaban
[1]
MA
[2008]
1 51 Clinical
behavior
EHDs Results considered satisfactory:
no further follow-up required
PMID: 24858823
Strontium
ranelate [2]
REF
[2012]
1 15 Clinical
knowledge
Questionnaire Study was considered
unsatisfactory
(methodological issues). New
risk minimization measures
and studies requested due to
additional regulatory actions
taken during the conduct of
this study (see ongoing studies
in electronic supplementary
material 1)
NA
Tolvaptan [1] MA
[2009]
1 65 Multiple
(with
safety
outcomes)
Primary data Study reported evidence of non-
compliance with
recommended dose. New
studies required to evaluate
the efficacy and safety of a
lower starting/ maintenance
dose
NCT01228682
(no results
posted)
Vildagliptin
(mono and
FDC) [6]
MA [2007,
2008]
1 62c Clinical
behavior
EHDs Results considered satisfactory:
no further follow-up required
NA
Additional
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Table 3 continued
INN [no. of
medicinal
products]
Type of
regulatory
procedure
[year]a
No. of
studies
CSR
submission
(months)b
Study
endpoint
Data source Regulatory outcome Study publication
Agalsidase
beta [1]
LE [2011] 1 22 Clinical
knowledge
Questionnaire Study considered unsatisfactory
(low recruitment/drug uptake).
Company proposal to measure
the impact of RMM by SRS
accepted. Reconsideration for
future surveys when
considered feasible
NA
Dronedarone
[1]
MA
[2009]
1 30 Clinical
behavior
Questionnaire Study terminated early due to
the outcome of an EU referral,
where further risk
minimization measures and
new studies were requested
(see ongoing studies in
electronic supplementary
material 1)
NA
Imiglucerase
[1]
LE [2010] 1 27 Clinical
knowledge
Questionnaire Study considered unsatisfactory
(low recruitment/drug uptake).
Company proposal to measure
the impact of RMM by SRS
accepted. Reconsideration for
future surveys when
considered feasible
NA
Insulin
degludec [1]
MA
[2012]
1 23 Clinical
knowledge
Other (focused
usability test)
Results considered satisfactory;
no further follow-up required
NA
Pioglitazone
(mono and
FDC) [5]
REF
[2011]
2 35 [a, b]
Multiple
(with
safety
outcomes)
[a, b] EHDs Results considered satisfactory;
however, new studies
requested to investigate the
use and effectiveness of RMM
in the management of the risk
of bladder cancer (see ongoing
studies in electronic
supplementary material 1)
[a] EUPAS10001
[b] EUPAS9998
Pioglitazone/
alogliptin
MA
[2013]
1d 21 Multiple
(with
safety
outcomes)
EHDs Study terminated early due to
low recruitment/drug uptake.
Information on this product
included in the ongoing DUS
for pioglitazone-containing
products (see ongoing studies
in electronic supplementary
material 1)
NA
Prasugrel [1] MA
[2008]
2 64 [a] Clinical
behavior
[b] Multiple
(with
safety
outcomes)
[a] EHDs
[b] Primary data
Results considered satisfactory;
no further follow-up required
[a] PMID:
27299993
[b] PMID:
25794517
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because new safety restrictions were requested during the
conduct of the study.
Information on design, methods, and results was made
publicly available in 9 of 24 studies, although the results
were reported in only 6 studies (4 publications in peer-
reviewed journals).
4 Discussion
4.1 Principal Findings
This is the first overview of industry-sponsored studies on
the effectiveness of RMMs in designated therapeutic areas,
with a focus on study design characteristics and regulatory
outcomes. We identified 59 studies that measured the
impact of RMMs. The analysis of these studies highlights
the need for process and methodological improvement in
the approaches to risk minimization effectiveness
evaluation.
There are a number of different conceptual models
published as guides for developing efficient strategies for
measuring the effectiveness of RMMs [18, 21–23]. These
models recommend for a comprehensive evaluation of risk
minimization, a multifocal, integrated measurement,
including each of the different elements of a set of RMMs,
particularly the assessment of the implementation of risk
minimization tools, such as acquired clinical knowledge of
targeted stakeholders (i.e. patients and HCPs), as well as
desired behavioral changes. They also emphasize that
demonstrating the reduction of the occurrence or severity
of ADRs (i.e. safety outcomes) is the ultimate endpoint to
assess attainment of risk minimization objectives since this
provides an overall measure of the level of risk control that
has been achieved with any RMM in place. Therefore,
robust evaluations are longitudinal in nature and should
include pretesting of the risk minimization tools, the
effectiveness of implementation, and the evaluation of the
safety outcomes.
However, in designing an evaluation strategy, careful
consideration should be given to the particular aspects of
implementation and outcome which can be realistically
measured to support regulatory decisions. Therefore, when
assessment of safety outcomes is considered unfeasible or
would incur unacceptable delay, pharmaceutical companies
and regulators may agree on evaluation of implementation
measures as a way to define the success of the RMM. These
measures might provide insight into the effectiveness of the
RMM, although there is no certainty that successful
implementation corresponds with reduction in occurrence
and/or severity of ADRs [6].
In our analysis, 15 studies were designed to measure
safety outcomes and 8 of these required primary data col-
lection or retrospective manual review of medical charts to
retrieve information on either adverse events reactions
reported or clinical outcomes that could reflect the occur-
rence or severity of ADRs. We have also demonstrated that
studies using primary data require around 5 years for the
finalization of the CSR, thus explaining the higher pro-
portion of studies evaluating implementation measures and
using alternative data sources. Evaluation of safety out-
comes might rely on EHDs because they provide rapid
information on drug exposure and patient clinical out-
comes, mainly based on secondary data collection in an
outpatient setting (i.e. primary care databases) [12, 24].
However, EHDs may not capture sufficient clinical
Table 3 continued
INN [no. of
medicinal
products]
Type of
regulatory
procedure
[year]a
No. of
studies
CSR
submission
(months)b
Study
endpoint
Data source Regulatory outcome Study publication
Ranolazine
[1]
MA
[2008]
1 84 Clinical
knowledge
Questionnaire Study considered unsatisfactory
(methodological issues).
Further expansion of the target
population requested
NA
INN international non-proprietary name, CSR clinical study report, DUS drug utilization study, EHDs electronic healthcare databases, EXT
extension of indication, EUPAS European Union Electronic Register of Post-Authorisation Studies identification number, FDC fixed-dose
combination, LE line extension, MA marketing authorization, NA not available, NCT US registry of clinical trials, PMID PubMed identification
number, REF referral, RMM risk minimization measure, SRS spontaneous reporting system
aThe year refers to the end date of the regulatory procedure
bTime to submission of the CSR from the end date of the regulatory procedure. In case of more studies for a single regulatory procedure, the date
of the last CSR submitted has been considered
cCalculated from the date of the first authorized product
dStudy requested in the context of the marketing authorization of this product because of the referral conducted for pioglitazone-containing
products finalized in July 2011
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outcome data [25] and integration with external sources
such as hospital databases, disease/drug registries, and
primary data may be challenging. This is reflected in our
findings where only 6 of 15 studies used EHDs to measure
safety outcomes.
Limited readily available information might also explain
the differences observed in measuring the effectiveness of
routine versus additional RMMs, particularly the higher
proportion of studies using questionnaires and testing the
clinical knowledge of the additional risk minimization
tools and their key messages. Medicinal products with
aRMMs are often used for treating serious diseases in a
hospital setting, and information on drug exposure may be
limited in EHDs [25]. The results of a recent study [22]
showed that it remains challenging to perform aRMM
effectiveness evaluation in a timely and appropriate way
and that approaches that go beyond the use of EHDs are
needed to allow the assessment of behavioral changes and
clinical knowledge.
Questionnaire-based studies might be helpful for col-
lecting information on patients’ or HCPs’ knowledge,
attitudes, behavior, and medication use in the absence of
readily available data. However, these surveys have chal-
lenges (e.g. recruiting participants, small or unrepresenta-
tive sample sizes) that make it difficult to draw robust
conclusions [7]. Moreover, they rely on the respondent’s
self-reporting and might provide socially acceptable re-
sponses, which have a large impact on the validity of
proposed questionnaires and study findings [26].
The use of quasi-experimental designs to measure the
impact of RMMs has been supported by a consensus panel
discussing preferred methodologies for evaluating US FDA
regulatory actions [13] because of their ability to estimate the
effect size of outcome measures before and after risk mini-
mization is introduced. The panel also highlighted the
importance of using ITS, particularly when it is worth
investigating the net effect of the intervention controlled for
potential biases, such as underlying secular trends, seasonal
effects, and random fluctuations [13, 27]. Our findings
reported eight quasi-experimental studies and, among them,
only one ITS design, thus suggesting that feasibility and
operational reasons might have limited the ability to employ
an appropriate design. However, there are certain conditions
that should be met for a quasi-experimental study to be
conducted, particularly the availability of pre-intervention
information. In our analysis, 27 studies were requested at the
time of the marketing authorization and 17 studies related to
medicinal products with OTC or restricted medical pre-
scription status for which pre-intervention information was
unavailable. In the absence of pre-intervention information,
the comparison of an outcome frequency measure obtained
post-intervention against a predefined reference value (e.g.
literature review, historical data, outcome frequency in the
prelicensing clinical trials) may be considered [6, 18].
However, such an approach was not proposed in the analysis
plan of any of the studies reviewed here.
With regard to the regulatory outcomes, 21 of 24 CSRs
were submitted within the agreed timeframe and 17 pro-
vided results that supported immediate regulatory deci-
sions. It should be noted that for 8 studies, the EMA’s
committees acknowledged there were justified reasons for
postponing the original due date, while the results of 7
CSRs were considered either outdated or of limited value,
prompting the need for further evaluation of the RMMs.
These findings suggest the requirement for more careful
consideration and justification by the pharmaceutical
companies of the proposed risk minimization evaluation in
terms of objectives, design, and feasibility. They also
suggest the need for a more comprehensive approach not
limited to a single element of the risk minimization strat-
egy and capable of generating different lines of evidence at
relevant intervals to help regulators to promptly assess
decision-relevant information. The utility of this approach
has been recently emphasized in an EU referral on the
fixed-dose combination of cyproterone and ethinylestradiol
and the risk of thromboembolism. Here, the PRAC agreed
that the assessment of the effectiveness of the aRMMs in
place could benefit from both a drug utilization study and a
questionnaire-based survey on clinical knowledge because
of the complementarity of the information that would be
provided [28]. Finally, our findings suggest that more effort
is needed to ensure that study results are made publicly
available to help advance the science of risk minimization
evaluation by facilitating peer review of protocols and
results, and encourage collaboration among stakeholders.
4.2 Strengths and Limitations of the Study
This is the first review of industry-sponsored studies
measuring the impact of RMMs with access to relevant
documents that also included published and unpublished
CSRs, integrating the assessment of study design and
regulatory outcomes. However, the study has some limi-
tations. First, we selectively included medicinal products
authorized for cardiovascular, endocrinology and meta-
bolic indications for the review. These represent a sub-
stantial proportion (29.7%) of all medicinal products
authorized during the study period and mainly focus on
targeted populations (i.e. chronic and elderly users)
potentially at higher risk for ADRs [29, 30]. However,
there are differences compared with other drug classes in
terms of patient characteristics, therapeutic indications, and
posology, which might lead to differences in either the risk
minimization strategy or the type of studies employed to
assess effectiveness, as observed in a recent study from
Zomerdijk et al. [31].
G. Mazzaglia et al.
Second, the initial study selection was based on titles
and objectives as reported in the EU-RMP and could have
resulted in an incomplete selection of the eligible studies.
Although the risk of overlooking studies has been mini-
mized by the selection being undertaken by two indepen-
dent reviewers, this bias cannot be completely ruled out.
Third, the EU-RMP does not necessarily include all studies
being performed to measure the impact of RMMs. How-
ever, the focus of this review was to give a snapshot of
those studies submitted by pharmaceutical companies to
the competent authorities as a part of a regulatory
requirement and included in the EU-RMP. Therefore, we
are confident that our sample provides a representative
picture of the risk minimization evaluation strategies in
place for the medicinal products authorized by the EMA in
the designated therapeutic areas.
5 Conclusions
We have observed that studies measuring any single end-
point to assess the effectiveness of the RMM may have
limitations, particularly uncertainties in predicting the
overall success, inability to provide timely results, and
feasibility issues. This indicates that due to the multilevel,
multistakeholder nature of RMMs, no single methodology
may be sufficient for conducting a robust evaluation of
program implementation and impact on safety outcomes.
Therefore, for efficient and effective evaluation, con-
sideration should be given to employing a range of meth-
ods that generate scientifically rigorous information on
different elements of the implementation of RMMs within
an agreed timeframe. These include enablers and barriers
for optimal program delivery and success, stakeholders’
knowledge, attitudes and perception of risk, and intended
and observed clinical behavior, with the ultimate focus
ideally on safety outcomes.
Moreover, to facilitate assessment of a risk minimiza-
tion program, besides the need for well-defined RMMs
with clear objectives, it is essential that pharmaceutical
companies and regulatory authorities agree on measurable
indicators of success to be included in the evaluation plan.
Optimal risk minimization evaluation may be hampered by
the limited information on drug exposure and clinical
outcomes when the RMM is introduced, therefore early
decisions are needed on the most appropriate reference
values.
Most importantly, a multifocal, integrated approach to
evaluation of RMMs should provide an efficient way to
allow rapid and timely assessment of decision-relevant
information, which is necessary to modify RMMs and
improve implementation at early stages, if needed, to fur-
ther strengthen patient protection.
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